Cargando…

Revolutionizing Alzheimer's disease and clinical trials through biomarkers

The Alzheimer's Association's Research Roundtable met in May 2014 to explore recent progress in developing biomarkers to improve understanding of disease pathogenesis and expedite drug development. Although existing biomarkers have proved extremely useful for enrichment of subjects in clin...

Descripción completa

Detalles Bibliográficos
Autores principales:	Mattsson, Niklas, Carrillo, Maria C., Dean, Robert A., Devous, Michael D., Nikolcheva, Tania, Pesini, Pedro, Salter, Hugh, Potter, William Z., Sperling, Reisa S., Bateman, Randall J., Bain, Lisa J., Liu, Enchi
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Elsevier 2015
Materias:	Diagnostic Assessment & Prognosis
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4879481/ https://www.ncbi.nlm.nih.gov/pubmed/27239522 http://dx.doi.org/10.1016/j.dadm.2015.09.001

Ejemplares similares

Insulin resistance is related to cognitive decline but not change in CSF biomarkers of Alzheimer's disease in non‐demented adults
por: Ennis, Gilda E., et al.
Publicado: (2021)

Random forest to differentiate dementia with Lewy bodies from Alzheimer's disease
por: Dauwan, Meenakshi, et al.
Publicado: (2016)

Alzheimer's biomarkers in daily practice (ABIDE) project: Rationale and design
por: de Wilde, Arno, et al.
Publicado: (2017)

Challenges associated with biomarker-based classification systems for Alzheimer's disease
por: Illán-Gala, Ignacio, et al.
Publicado: (2018)

Periodontal disease's contribution to Alzheimer's disease progression in Down syndrome
por: Kamer, Angela R., et al.
Publicado: (2016)

Alzheimer's disease severity, objectively determined and measured
por: Gross, Alden L., et al.
Publicado: (2016)

Prognostic value of ATN Alzheimer biomarkers: 60‐month follow‐up results from the Argentine Alzheimer's Disease Neuroimaging Initiative
por: Allegri, Ricardo F., et al.
Publicado: (2020)

The Wisconsin Registry for Alzheimer's Prevention: A review of findings and current directions
por: Johnson, Sterling C., et al.
Publicado: (2017)

Function and clinical meaningfulness of treatments for mild Alzheimer's disease
por: Siemers, Eric, et al.
Publicado: (2016)

Detection of presymptomatic Alzheimer's disease through breath biomarkers
por: Emam, Shadi, et al.
Publicado: (2020)

Is diabetes associated with increased pathological burden in Alzheimer's disease?
por: Sadrolashrafi, Kaviyon, et al.
Publicado: (2021)

Metabolic correlates of prevalent mild cognitive impairment and Alzheimer's disease in adults with Down syndrome
por: Mapstone, Mark, et al.
Publicado: (2020)

Development and validation of a salivary tau biomarker in Alzheimer's disease
por: Pekeles, Heather, et al.
Publicado: (2018)

Assessing quality of life in Alzheimer's disease: Implications for clinical trials
por: Kahle-Wrobleski, Kristin, et al.
Publicado: (2016)

Multimodal prediction of conversion to Alzheimer's disease based on incomplete biomarkers
por: Ritter, Kerstin, et al.
Publicado: (2015)

The Consortium for the early identification of Alzheimer's disease–Quebec (CIMA-Q)
por: Belleville, Sylvie, et al.
Publicado: (2019)

Theoretical frameworks and approaches used within the Reserve, Resilience and Protective Factors professional interest area of the Alzheimer's Association International Society to Advance Alzheimer's Research and Treatment
por: Bartrés‐Faz, David, et al.
Publicado: (2020)

Relationship between frailty and Alzheimer's disease biomarkers: A scoping review
por: Wallace, Lindsay, et al.
Publicado: (2018)

Copper and zinc isotopic excursions in the human brain affected by Alzheimer's disease
por: Moynier, Frédéric, et al.
Publicado: (2020)

Diagnosed prevalence of Alzheimer's disease and related dementias in Medicare Advantage plans
por: Jutkowitz, Eric, et al.
Publicado: (2020)

Clinical and biomarker trajectories in sporadic Alzheimer's disease: A longitudinal study
por: Wang, Hui‐Fu, et al.
Publicado: (2020)

Women's higher brain metabolic rate compensates for early Alzheimer's pathology
por: Sundermann, Erin E., et al.
Publicado: (2020)

Moderate intensity physical activity associates with CSF biomarkers in a cohort at risk for Alzheimer's disease
por: Law, Lena L., et al.
Publicado: (2018)

Characterizing heterogeneity in the progression of Alzheimer's disease using longitudinal clinical and neuroimaging biomarkers
por: Goyal, Devendra, et al.
Publicado: (2018)

Early diagnosis of mild cognitive impairment and Alzheimer's disease based on salivary lactoferrin
por: Carro, Eva, et al.
Publicado: (2017)

Cerebrospinal fluid biomarkers of Alzheimer's disease in a cohort of adults with Down syndrome
por: Henson, Rachel L., et al.
Publicado: (2020)

Developmental lead exposure and lifespan alterations in epigenetic regulators and their correspondence to biomarkers of Alzheimer's disease
por: Eid, Aseel, et al.
Publicado: (2016)

Pilot study of an Alzheimer's disease risk assessment program in a primary care setting
por: Korthauer, Laura E., et al.
Publicado: (2021)

Standardizing salivary lactoferrin measurements to obtain a robust diagnostic biomarker for Alzheimer's disease
por: Bartolome, Fernando, et al.
Publicado: (2021)

Patterns of glucose hypometabolism in Down syndrome resemble sporadic Alzheimer's disease except for the putamen
por: Zammit, Matthew D., et al.
Publicado: (2021)

Meeting physical activity recommendations may be protective against temporal lobe atrophy in older adults at risk for Alzheimer's disease
por: Dougherty, Ryan J., et al.
Publicado: (2016)

Trends in health service use and potentially avoidable hospitalizations before Alzheimer's disease diagnosis: A matched, retrospective study of US Medicare beneficiaries
por: Desai, Urvi, et al.
Publicado: (2019)

Tauopathy in basal ganglia involvement is exacerbated in a subset of patients with Alzheimer's disease: The Hisayama study
por: Hamasaki, Hideomi, et al.
Publicado: (2019)

Bayesian latent time joint mixed-effects model of progression in the Alzheimer's Disease Neuroimaging Initiative
por: Li, Dan, et al.
Publicado: (2018)

Learning to classify neural activity from a mouse model of Alzheimer's disease amyloidosis versus controls
por: Beker, Shlomit, et al.
Publicado: (2016)

Longitudinal evaluation of criteria for subjective cognitive decline and preclinical Alzheimer's disease in a memory clinic sample
por: Eckerström, Marie, et al.
Publicado: (2017)

Clinico‐pathological comparison of patients with autopsy‐confirmed Alzheimer's disease, dementia with Lewy bodies, and mixed pathology
por: Chatterjee, Atri, et al.
Publicado: (2021)

Effects of vascular risk factors, statins, and antihypertensive drugs on PiB deposition in cognitively normal subjects
por: Glodzik, Lidia, et al.
Publicado: (2016)

What outcomes are important to patients with mild cognitive impairment or Alzheimer's disease, their caregivers, and health-care professionals? A systematic review
por: Tochel, Claire, et al.
Publicado: (2019)

Disclosure of preclinical Alzheimer's disease biomarker results in research and clinical settings: Why, how, and what we still need to know
por: Erickson, Claire M., et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_scf401rp7k259vdrs0bgbs8ukk